KPV Lead · BPC-157 / TB-500 / GHK-Cu / KPV · Protocol Guide
KLOW (KPV Stack): The Honest Four-Peptide Repair Guide
KLOW is a single vial that combines four healing peptides. The lead active worth understanding first is KPV, the anti-inflammatory tripeptide cut from the tail of alpha-MSH. Its preclinical gut and colitis data are genuinely interesting. This guide centers KPV, then explains the rest of the stack and says plainly that the four-peptide blend has no combined human trial behind it.
- FDA Status
- Investigational, 503A Compounded
- Pharmacy
- Optimal Balance Pharmacy (503A licensed)
- Medical Service
- RxPepsDirect, physician-supervised
- Access
- 28 U.S. States
Our promise: KPV has real, repeatable anti-inflammatory data, but almost all of it is in animal models of colitis, and much of it was delivered in engineered nanoparticles, not as a plain injection. The other three peptides in KLOW carry their own separate evidence. The four-peptide KLOW blend itself has never been tested as a unit in a human trial. We label each of those lines as we cross it.
Medically reviewed by Dr. Jonathan Snipes, MD. Last reviewed June 8, 2026.On this page
Section 01
What KLOW Actually Is
KLOW is a compounded combination vial that puts four peptides in a single daily injection: BPC-157, TB-500, GHK-Cu, and KPV. The name is an acronym of the four actives. It sits at the top of the recovery-and-repair ladder above the simpler BPC-157/TB-500 "Wolverine" pairing, adding copper-peptide skin and collagen support (GHK-Cu) and anti-inflammatory immune modulation (KPV) to the foundation.
The single most interesting molecule in that lineup, and the one this guide leads with, is KPV. It is a three-amino-acid fragment of alpha-melanocyte-stimulating hormone with a clean, repeatable anti-inflammatory signal in the lab. It is also the active with the biggest gap between mechanism and proof, which is exactly why it deserves a careful, honest read rather than a marketing line.
What KLOW is not is a clinically validated four-peptide therapy. There is no trial of the blend as a unit. It is a compounding decision that stacks four individually studied peptides on the bet that their mechanisms complement each other. That bet is reasonable. It is also untested in people, and we will not pretend otherwise.
4
Peptides combined in one vial: BPC-157, TB-500, GHK-Cu, KPV
3
Amino acids in KPV, the lead anti-inflammatory active (Lys-Pro-Val)
0
Human trials of the KLOW blend as a single combined product
503A
Pathway for U.S. compounded access under physician prescription
Section 02
KPV: The Lead Active
KPV is the C-terminal tripeptide of alpha-melanocyte-stimulating hormone, the last three residues (lysine, proline, valine) of a much larger hormone. Alpha-MSH itself is a potent anti-inflammatory mediator, but its broader effects, including pigmentation, limited its use as a drug. The striking finding, documented in a 2010 review in Advances in Experimental Medicine and Biology, is that KPV keeps almost all of alpha-MSH's anti-inflammatory capacity while losing the sequence needed to bind the known melanocortin receptors, and without any pigment action.
That receptor-independent behavior is the puzzle and the appeal. KPV calms inflammation without acting through the receptors you would expect, which is partly why it has been studied as an alternative to the full hormone for inflammatory bowel and skin disease. The exact signaling it uses is still not fully mapped, a point the review states directly.
Cut From Alpha-MSH
KPV is alpha-MSH(11-13), the final three amino acids of the hormone. It retains the anti-inflammatory tail while dropping the receptor-binding and pigment-driving body of the molecule.
NF-kB Dampening
Across the alpha-MSH peptide family, a consistent theme is reduced NF-kB activation, the master switch for inflammatory gene expression. KPV appears to share this signaling overlap with the parent hormone.
Receptor-Independent
KPV lacks the motif needed to bind known melanocortin receptors, yet keeps the anti-inflammatory effect. Some of its action in colitis models was even preserved in animals with a nonfunctional MC1 receptor.
Mucosal Healing Signal
In gut models, KPV did two things at once: lowered inflammatory markers and supported mucosal recovery. The repair signal, not just the calming signal, is part of what makes it interesting.
Section 03
The Four-Peptide Stack
KLOW pairs KPV with three other repair peptides, each chosen for a distinct mechanism. Per the catalog formulation, the vial delivers BPC-157 15 mg, GHK-Cu 50 mg, KPV 15 mg, and TB-500 15 mg per 5 mL (no separate component is sold as the headline here, the blend is the product). The logic is breadth: cover local repair, systemic recovery, collagen remodeling, and inflammation in one shot.
| Peptide | Role in the Blend | Evidence Basis | Confidence |
|---|---|---|---|
| KPV (lead active) | Anti-inflammatory tripeptide from alpha-MSH; NF-kB dampening, mucosal support | Repeated preclinical colitis and IBD data; much of it nanoparticle-delivered. [1][2][3][4][5] | Preclinical, Consistent |
| BPC-157 | Local tissue repair and angiogenesis; gut and tendon healing | Large animal literature, mostly from one research group. [6] | Preclinical |
| TB-500 (thymosin beta-4 fragment) | Cell migration to injury sites, systemic recovery | Mechanistic and animal data; limited controlled human work. | Thin Human Data |
| GHK-Cu | Copper-peptide collagen and elastin synthesis, skin remodeling | Best evidence is topical/skin; injectable systemic use is less studied. | Mostly Topical Data |
Peptide
Role in the Blend
Evidence Basis
Confidence
Peptide
Role in the Blend
Evidence Basis
Confidence
Peptide
Role in the Blend
Evidence Basis
Confidence
Peptide
Role in the Blend
Evidence Basis
Confidence
Section 04
Who It Is Actually For
The honest fit assessment leans on each peptide's own data, because the blend has none of its own. KPV's evidence pulls the inflammatory-condition use cases up; the lack of combined human data holds the general-recovery use cases in check.
| Profile | Primary Motivation | Evidence Basis | Fit |
|---|---|---|---|
| Injury Recovery With Inflammation | Tissue repair plus a strong anti-inflammatory component | Each peptide's mechanism applies; KPV adds the anti-inflammatory rationale. | Best Rationale |
| Post-Surgical Or Multi-Site Recovery | Several tissues healing at once, broad coverage in one shot | Extrapolated from BPC-157 and TB-500 repair models. No combined trial. | Reasonable Fit |
| Gut-Focused Healing Goals | Inflammatory gut symptoms, mucosal support | KPV and BPC-157 both have gut-model data, but not as this blend or this route. | Exploratory |
| General Recovery / Biohacking Use | Broad anti-inflammation and repair without a specific injury | Extrapolated from preclinical models. The combination is untested in people. | Speculative |
| Active Malignancy | Recovery support during or after cancer treatment | Growth and angiogenic signaling raises a theoretical concern; flagged in the catalog. | Provider Review First |
Profile
Primary Motivation
Evidence Basis
Fit
Profile
Primary Motivation
Evidence Basis
Fit
Profile
Primary Motivation
Evidence Basis
Fit
Profile
Primary Motivation
Evidence Basis
Fit
Profile
Primary Motivation
Evidence Basis
Fit
Section 05
How KLOW Works
KLOW is best understood as four parallel mechanisms delivered together, not a single unified action. KPV carries the anti-inflammatory load; the other three carry repair and remodeling from different angles.
KPV: Inflammation Brake
The alpha-MSH-derived tripeptide dampens NF-kB-driven inflammatory signaling and, in gut models, supported mucosal recovery. This is the anti-inflammatory backbone of the stack.
BPC-157: Local Repair
In animal models the stable gastric pentadecapeptide promotes angiogenesis and tissue, tendon, and gut healing. It is the local-repair workhorse of the blend.
TB-500: Cell Migration
A thymosin beta-4 fragment associated with moving repair cells toward injured tissue and supporting systemic recovery. It widens the repair effect beyond the injection site.
GHK-Cu: Collagen Remodeling
A copper-binding tripeptide tied to collagen and elastin synthesis and skin remodeling. Its strongest evidence is topical, so its systemic injectable contribution is the least certain.
Section 06
What the Evidence Shows
This is the section that matters most for KLOW, because the gap between the marketing and the proof is wide. Based on articles retrieved from PubMed, here is the actual record for the lead active and the foundation peptide, in order. Note up front that there is no KLOW combination trial to list.
| Study | Design | Key Finding | Strength |
|---|---|---|---|
| Kannengiesser 2008 (IBD) [1] | Two murine colitis models (DSS and transfer colitis) | KPV led to earlier recovery, body-weight regain, and significantly reduced inflammatory infiltrate and myeloperoxidase; effect partly independent of MC1R. | Animal, Strong Signal |
| Laroui 2010 (Gastroenterology) [2] | KPV nanoparticle, DSS colitis mouse model | Colon-targeted KPV nanoparticles reduced inflammation at doses 12,000-fold lower than free KPV in solution. | Animal, Engineered Delivery |
| Xiao 2017 (Mol Ther) [3] | Oral hyaluronic-acid KPV nanoparticle, UC mouse model | Accelerated mucosal healing and lowered TNF-alpha; better efficacy than the nanoparticle alone. | Animal, Engineered Delivery |
| Brzoska 2010 (review) [4] | Review of alpha-MSH-derived peptides | KPV retains nearly all anti-inflammatory capacity of alpha-MSH without melanocortin-receptor binding or pigment effect; signaling not fully defined. | Narrative Review |
| Sun 2021 (ACS Biomater) [5] | KPV hydrogel, TNBS colitis rat model | Stabilized rectal KPV reduced disease activity, colon shortening, and pro-inflammatory cytokines. | Animal, Stabilized Delivery |
| Seiwerth 2018 (review) [6] | Review of BPC-157 healing across tissues | BPC-157 was consistently effective across animal models of gastrointestinal, tendon, ligament, muscle, and bone healing. | Narrative Review, Animal |
Study
Design
Key Finding
Strength
Study
Design
Key Finding
Strength
Study
Design
Key Finding
Strength
Study
Design
Key Finding
Strength
Study
Design
Key Finding
Strength
Study
Design
Key Finding
Strength
Section 07
Realistic Expectations
KLOW is a repair-and-calm compound, not a stimulant. There is no day-one effect to chase. If it helps, it does so gradually, through lowered inflammation and supported tissue repair, over weeks.
Little Felt Effect
Expect to feel little directly. The peptides act on repair and anti-inflammatory pathways, not on receptors that produce an immediate subjective response. A quiet start is normal and tells you nothing about whether you will respond.
Early Inflammation Signals
Some users report reduced soreness, swelling, or inflammatory discomfort around this point. This is the earliest window where a real change tends to surface, and it is inherently individual.
Repair Phase
Tissue repair is slow biology. In responders, recovery and inflammatory complaints continue to improve across this window rather than resolving all at once.
Course Reassessment
A single course is a natural point to reassess with your prescriber and decide whether to pause, repeat, or stop. There is no validated long-run protocol for the blend.
Section 08
Dosing Protocol
KLOW dosing is practical, not trial-derived, because no combination trial exists. The standard prescribed approach uses a single daily injection on a weekday schedule, with your RxPepsDirect physician adjusting by response and tolerance.
| Context | Dose | Route / Frequency | Evidence Basis |
|---|---|---|---|
| RxPepsDirect Standard | 20 units (full stack) | Subcutaneous or IM, daily Monday to Friday | Clinical Practice |
| Per-Injection Delivery | BPC-157 0.6mg + GHK-Cu 2mg + KPV 0.6mg + TB-500 0.6mg | 0.2mL per 20-unit dose | Formulation |
| Course Length | Physician-set | Typically 4 to 12 weeks, may be cycled | Practice, Not Trial |
| Combination Trial Dose | None exists | No human study of the blend to anchor a dose | No Validated Dose |
Context
Dose
Route / Frequency
Evidence Basis
Context
Dose
Route / Frequency
Evidence Basis
Context
Dose
Route / Frequency
Evidence Basis
Context
Dose
Route / Frequency
Evidence Basis
Subcutaneous injection into abdominal fat with a standard insulin syringe, or intramuscular per your prescriber. Rotate sites. Twenty units delivers 0.2 mL of the combined vial. Timing is flexible because none of the four peptides aligns with a hormonal pulse; most patients dose in the morning for routine consistency. The weekday-only schedule gives a built-in two-day pause each week.
Section 09
Ready to Inject
0
Reconstitution steps required
503A
Licensed pharmacy (Optimal Balance), physician-supervised
Overnight
FedEx shipping in a reusable cooled travel case
Section 10
Safety and Side Effects
KLOW's safety profile is inherited from its four components and the short, mostly preclinical record behind them. The most honest statement is that long-term human safety of this specific blend has not been formally characterized. Injection-site reactions are the most routine practical issue.
| Consideration | Detail | Action |
|---|---|---|
| Injection site reaction | Mild redness or irritation, the most common practical event | Rotate sites. Let the vial warm slightly before injecting. |
| Active malignancy | Repair and angiogenic signaling raises a theoretical concern | Flag for provider review before starting. Catalog flags this explicitly. |
| Autoimmune conditions | Immune-modulating peptides warrant monitoring | Tell your prescriber so they can monitor and confirm fit. |
| Copper sensitivity | GHK-Cu is a copper-binding peptide | Disclose any known copper allergy or copper-handling disorder. |
| Pregnancy / lactation | No safety data | Avoid. |
Consideration
Detail
Action
Consideration
Detail
Action
Consideration
Detail
Action
Consideration
Detail
Action
Consideration
Detail
Action
Section 11
Stacking
Pairs Well With
CJC-1295 / Ipamorelin
A bedtime growth-hormone stack complements daytime KLOW repair without timing conflict. The catalog lists this as KLOW's natural pairing.
GHK-Cu (topical)
Topical copper-peptide skincare targets the surface while KLOW works systemically. Different routes, complementary collagen support.
ARA-290
Innate-repair-receptor anti-inflammation through a separate pathway, for nerve-focused complaints alongside KLOW's broad repair.
Avoid or Use Caution
Redundant BPC-157 or TB-500 vials
KLOW already contains both. Stacking a separate BPC-157/TB-500 vial on top double-doses two of the four actives with no added rationale.
Active malignancy
Repair and angiogenic signaling is a theoretical concern. Provider review before use.
Pregnancy / lactation
No safety data. Avoid.
Section 12
Pricing
Pharmacy: Medication
$120 per vial. Compounded and shipped by Optimal Balance Pharmacy, a 503A licensed compounding pharmacy. Pre-reconstituted four-peptide blend, FedEx overnight.
Medical Service: Physician Consultation
$39 medical visit fee. Intake consultation including symptom review, protocol design, prescription writing, and follow-up. Billed by RxPepsDirect for the medical service only.
Section 13
Legal Access in 28 States
503A Licensed Pharmacy
Optimal Balance Pharmacy, U.S. licensed
Physician Prescription Required
Compounded medication, Rx only
Investigational Peptides
Preclinical evidence, no FDA approval
Off-Label, Legal Practice
Standard and legal in U.S. medicine
The peptides in KLOW are investigational. None of them is FDA-approved as a finished drug, and the four-peptide blend is a compounded preparation, not an approved product. In the United States it is available through 503A patient-specific compounding under a physician prescription. The 503A pathway is the documented legal route for compounded peptide access. RxPepsDirect prescribers serve patients in 28 states.
Section 14
Community Q&A
What is KPV and why is it the lead peptide in KLOW?
KPV is a three-amino-acid peptide (lysine, proline, valine) from the C-terminal tail of alpha-MSH. It keeps most of the parent hormone's anti-inflammatory action but loses the pigment and receptor-binding parts. We lead with it because it has the clearest, most repeated preclinical data in the stack, mostly in animal models of colitis and inflammatory bowel disease.
Has the KLOW four-peptide blend been tested in humans?
No. There is no human trial of the combination as a single product. Each peptide has its own separate, mostly preclinical evidence, and KPV's strongest data used engineered nanoparticles rather than a plain injection. The blend is a compounding decision, not a tested clinical formula.
Is KPV's colitis data relevant to a recovery injection?
Only partly. Most of the strong KPV results treated inflamed gut tissue with the peptide packaged to reach the colon. A daily subcutaneous shot of free KPV for general recovery is a different route and a different goal. The mechanism is real; extending it to whole-body recovery is an extrapolation.
Should I take KLOW or just BPC-157/TB-500?
KLOW adds GHK-Cu and KPV to the BPC-157/TB-500 foundation. The honest answer is that no study has compared them head to head in people. You are choosing breadth and one injection over two, not a proven performance gap. Decide with your prescriber based on whether the added anti-inflammatory and collagen angles match your goal.
How long is a course?
There is no validated protocol for the blend. RxPepsDirect courses typically run 4 to 12 weeks, often dosed weekdays only, with your prescriber reassessing before any extension or repeat.
Section 15
The RxPepsDirect Model
Pharmacy: Optimal Balance, 503A Licensed
Optimal Balance Pharmacy compounds your KLOW under a patient-specific prescription, USP <797> sterile standards, and federal 503A oversight.
Medical Service: RxPepsDirect Physicians
A licensed physician reviews your history, screens for contraindications, designs your protocol, and writes your prescription. RxPepsDirect bills the $39 medical visit fee for this service.
Transparent Safety Communication
This guide flags that the KLOW blend has no combined human trial, that KPV's strongest data is preclinical and nanoparticle-based, that the other peptides carry thin human evidence, and that general recovery use is extrapolation. We do not hide limitations to make a sale.
Legal Access in 28 States
Every shipment is a compounded prescription medication filled by a 503A licensed pharmacy under a physician prescription.
References
- Kannengiesser K, Maaser C, Heidemann J, et al. Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease. Inflamm Bowel Dis. 2008. PMID: 18092346
- Laroui H, Dalmasso G, Nguyen HT, et al. Drug-loaded nanoparticles targeted to the colon with polysaccharide hydrogel reduce colitis in a mouse model. Gastroenterology. 2010. PMID: 19909746
- Xiao B, Xu Z, Viennois E, et al. Orally Targeted Delivery of Tripeptide KPV via Hyaluronic Acid-Functionalized Nanoparticles Efficiently Alleviates Ulcerative Colitis. Mol Ther. 2017. PMID: 28143741
- Brzoska T, Bohm M, Lugering A, et al. Terminal signal: anti-inflammatory effects of alpha-melanocyte-stimulating hormone related peptides beyond the pharmacophore. Adv Exp Med Biol. 2010. PMID: 21222263
- Sun J, Xue P, Liu J, et al. Self-Cross-Linked Hydrogel of Cysteamine-Grafted gamma-Polyglutamic Acid Stabilized Tripeptide KPV for Alleviating TNBS-Induced Ulcerative Colitis in Rats. ACS Biomater Sci Eng. 2021. PMID: 34547895
- Seiwerth S, Rucman R, Turkovic B, et al. BPC 157 and Standard Angiogenic Growth Factors. Gastrointestinal Tract Healing, Lessons from Tendon, Ligament, Muscle and Bone Healing. Curr Pharm Des. 2018. PMID: 29998800
Related protocol guides
Other protocols in the same clinical territory. Each guide is co-bylined by a licensed RxPepsDirect prescriber.
Recovery peptide protocol
BPC-157 protocol guide: clinical data, physician dosing, and the limits of the evidence
Mechanism, dosing, non-response rates, the angiogenesis question, WADA status, and the 503A pathway. Honest about what the human evidence is and is not.
Copper tripeptide (skin & tissue)
GHK-Cu protocol guide: collagen, the copper uglies, and the topical vs injectable evidence gap
Topical has human RCT support. Injectable for cosmetic claims is anecdotal. The copper uglies are real and manageable. Hair-loss support, yes; DHT blocker, no.
EPO-derived repair peptide protocol
ARA-290 (cibinetide) protocol guide: innate repair receptor, the neuropathy trials, and the non-erythropoietic difference
An 11-amino-acid fragment of erythropoietin that triggers tissue repair without EPO's blood-thickening effect. Human evidence is small Phase 2 neuropathy trials. Honest about where the data stops.
Continue reading